The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

In trading on Friday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) crossed above their 200 day moving average of $458.68, changing hands as high as $469.00 per share. Vertex ...

Vertex Pharmaceuticals Incorporated (VRTX) stock price is 461.68 and Vertex Pharmaceuticals Incorporated (VRTX) 10-day simple moving average is 438.34. Vertex Pharmaceuticals Incorporated (VRTX ...

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal... ByInvesting.com • Oct ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

This was the stock's second consecutive day of losses.

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

The stock's fall snapped a four-day winning streak.